Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at 50th ASH Annual Meeting and Exposition by NIH investigators
Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained so far in a physician initiated clinical study for ATIR™ led by Dr. Stephan Mielke* and Dr. John Barrett* of the National Heart, Lung, and Blood Institute (NHLBI), a department of the National Institutes of Health (NIH), at the 50th ASH Annual Meeting and Exposition to be held on December 6 - 9, 2008 at the Moscone Convention Center in San Francisco, USA.
Title poster: “Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies”
Session Name: Clinical Transplantation - Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution Poster I
Date: Saturday, December 6, 2008
Presentation Time: 5:30 PM - 7:30 PM
Location: Moscone Center, Hall A
Poster Board no.: I-273
Kiadis Pharma is developing ATIR™ for the prevention of acute Graft versus Host Disease (GvHD) and early immune reconstitution following an allogeneic bone marrow transplantation using mismatched donors. ATIR™ selectively eliminates immune cells that could otherwise attack the patient’s body after an allogeneic bone marrow transplantation and cause acute (GvHD). Because the risk for acute GvHD is eliminated, no immune suppressants have to be used post transplantation allowing early immune reconstitution in these patients reducing the risk of opportunistic infections. Eliminating the risk of acute GvHD and early immune reconstitution can improve the outcome of current allogeneic transplantations and, moreover, allows the use of a mismatched donor enabling virtually all eligible patients to find a donor. Kiadis Pharma’s ATIR™ product is under evaluation in two “mismatched donor” trials. The clinical phase II study by the NIH has extended the use of ATIR™ in HLA-matched transplantations.
About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit www.kiadis.com
Dr. John Barrett is the Chief of the Allotransplant Section at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, MD, USA, where the trial is being performed. Dr. Stephan Mielke, who initiated this study as principal investigator at the NHLBI, is currently working at the Julius-Maximilians University of Würzburg, Germany and continues as the lead associate investigator on the protocol.
- Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ 26-2-2013
- Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ 21-1-2013
- Kiadis Pharma Raises EUR 10 Million in Financing Round 20-11-2012
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma receives two orphan drug designations for Reviroc™ from the FDA 8-12-2008
- Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™ 4-12-2008